Developments in ¹⁷⁷Lu-based radiopharmaceutical therapy and dosimetry.

ABSTRACT: ¹⁷⁷Lu is a radioisotope that has become increasingly popular as a therapeutic agent for treating various conditions, including neuroendocrine tumors and metastatic prostate cancer. ¹⁷⁷Lu-tagged radioligands are molecules precisely designed to target and bind to specific receptors or proteins characteristic of targeted cancer. This review paper will present an overview of the available ¹⁷⁷Lu-labelled radioligands currently used to treat patients. Based on recurring, active, and completed clinical trials and other available literature, we evaluate current status, interests, and developments in assessing patient-specific dosimetry, which will define the future of this particular treatment modality. In addition, we will discuss the challenges and opportunities

SUBMITTER: George SC 

PROVIDER: S-EPMC10424930 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature